What to expect

1. Ask about an opportunity

Browse by location or contact us. Tell us which location and study interest you. Please use the study’s designated interest form or speak with our team before sharing detailed health information.

2. Discuss preliminary suitability

With the appropriate permission, we may discuss relevant history, medications, practical needs, and authorized existing records. BR-REC-001 pre-screening assesses whether formal screening is plausible. It does not guarantee a place or determine final eligibility.

3. Review the study and decide

The study team explains its purpose, procedures, risks, possible benefits, alternatives, and payment or costs. Ask for anything unclear to be explained. Consent is an ongoing conversation, not just a signature. Applicable study consent comes before study-specific screening procedures.

4. Complete screening, if you choose

The team follows the study’s requirements to determine eligibility. Screening may include examinations, tests, or questionnaires described in the consent. Only eligible volunteers can proceed to enrollment. Some trials assign treatment by chance or use a placebo; the team will explain whether that applies.

5. Participate and stay in touch

If enrolled, follow the agreed visit schedule and let the team know about symptoms, medication changes, and scheduling difficulties. Ask how to reach the team between visits. You may stop participating; discuss safe discontinuation and any requested follow-up with the study team.

Boeson’s initial pre-screening framework is BR-REC-001, Version 1.1, dated September 14, 2026, approved by Pearl IRB, IRB ID 2026-0457. It helps assess whether formal screening may be appropriate; it does not establish eligibility or enroll you in a trial. Separate studies have their own consent and oversight. Read our Privacy Statement for permissions, records, and contact choices.

Before your first visit

Confirm the address and appointment time, ask what to bring, and check whether any preparation is required. Do not fast or stop medicines unless the appropriate clinician has instructed you to do so.

Find a study near you · Ask our team a question · Locations and directions

Further reading: ACRP: Improving informed-consent communication.